国际检验医学杂志
國際檢驗醫學雜誌
국제검험의학잡지
INTERNATIONAL JOURNAL OF LABORATORY MEDICINE
2014年
22期
3072-3073
,共2页
刘德华%胡大春%卢赞%任宝军%王霞%周玲%钱净%秦海燕
劉德華%鬍大春%盧讚%任寶軍%王霞%週玲%錢淨%秦海燕
류덕화%호대춘%로찬%임보군%왕하%주령%전정%진해연
铜绿假单胞菌%抗菌药物%耐药
銅綠假單胞菌%抗菌藥物%耐藥
동록가단포균%항균약물%내약
Pseudomonas aeruginosa%antimicrobial agents%drug resistance
目的:回顾性研究临床分离铜绿假单胞菌的标本来源、病区分布、耐药状况及其变迁。方法采用MicroscanWalk‐away40鉴定药敏系统及传统手工方法对2002~2012年医院各类临床送检标本中分离到的1114株铜绿假单胞菌进行鉴定及药敏试验,对结果进行统计分析。结果1114株分离的铜绿假单胞菌中,有64.18%来自呼吸道标本。铜绿假单胞菌感染主要发生在重症监护病房(ICU)病房,占49.64%。2002~2012年间,铜绿假单胞菌对19种抗菌药物的耐药率总体呈上升趋势。结论铜绿假单胞菌常引起呼吸道感染,其耐药机制复杂,可选择的抗菌药物有限。
目的:迴顧性研究臨床分離銅綠假單胞菌的標本來源、病區分佈、耐藥狀況及其變遷。方法採用MicroscanWalk‐away40鑒定藥敏繫統及傳統手工方法對2002~2012年醫院各類臨床送檢標本中分離到的1114株銅綠假單胞菌進行鑒定及藥敏試驗,對結果進行統計分析。結果1114株分離的銅綠假單胞菌中,有64.18%來自呼吸道標本。銅綠假單胞菌感染主要髮生在重癥鑑護病房(ICU)病房,佔49.64%。2002~2012年間,銅綠假單胞菌對19種抗菌藥物的耐藥率總體呈上升趨勢。結論銅綠假單胞菌常引起呼吸道感染,其耐藥機製複雜,可選擇的抗菌藥物有限。
목적:회고성연구림상분리동록가단포균적표본래원、병구분포、내약상황급기변천。방법채용MicroscanWalk‐away40감정약민계통급전통수공방법대2002~2012년의원각류림상송검표본중분리도적1114주동록가단포균진행감정급약민시험,대결과진행통계분석。결과1114주분리적동록가단포균중,유64.18%래자호흡도표본。동록가단포균감염주요발생재중증감호병방(ICU)병방,점49.64%。2002~2012년간,동록가단포균대19충항균약물적내약솔총체정상승추세。결론동록가단포균상인기호흡도감염,기내약궤제복잡,가선택적항균약물유한。
Objective To retrospective analyze the specimens and wards distribution and the drug resistance changes of clinical i‐solated Pseudomonas aeruginosa .Methods 1 114 strains of Pseudomonas aeruginosa were isolated from a variety of clinical speci‐mens for the identification and susceptibility testing by using Microscan Walkaway40 identification and antibiotic susceptibility anal‐ysis system and manual method from 2002 to 2012 .And the results were analyzed .Results In all of the 1 114 isolated Pseudomonas aeruginosa strains ,there were 64 .18% of them from respiratory specimens .Pseudomonas aeruginosa infection occured mainly in the ICU wards (49 .64% ) .From 2002 to 2012 ,the drug resistance rates of Pseudomonas aeruginosa to 19 kinds of antibacterial drugs increased year by year .Conclusion Pseudomonas aeruginosa often causes respiratory tract infection ,and its mechanism of drug resistance is complex .There are few alternative antimicrobial drugs for the treatment of Pseudomonas aeruginosa infection .